Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/7319| Title: | Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience | Authors: | Crvenkova, Simonida Ivkovski, Lj Dimovski, A Kaeva, B |
Issue Date: | 2012 | Journal: | Prilozi | Abstract: | The aim of this study was to evaluate tumour response, QoL and adverse effects of erlotinib, EGFR tyrosine kinase inhibitor (TKI), as a second line therapy for patients with EGFR mutation in NSCLC, after failure of previous first-line therapy. | URI: | http://hdl.handle.net/20.500.12188/7319 | ISSN: | 0351-3254 |
| Appears in Collections: | Faculty of Medicine: Journal Articles |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.